...
FBIOMICRO

Fortress Biotech, Inc.

HealthcareBiotechnology
$3.42
$0.00(-2.84%)
52W$1.33
$4.53
FinancialsValuationvs REGN
Updated Mar 2, 12:00 AM
RSI52
RS Rating83/99
Beta0.65
Volatility79%
F-Score1/9
Mkt Cap$95M
EMERGING TREND

Price Action

5Y Daily
50 DMA150 DMA200 DMA

Technical Summary

EMERGING TREND

Fortress Biotech, Inc. shows underlying uptrend characteristics but has temporarily lost support at the 50-day moving average. Relative strength is leading (RS Rating: 83), indicating clear outperformance against the broad market. Earnings growth of 114% provides fundamental context to the price action. Investors should exercise caution due to high volatility (79% annualized), which requires wider risk management.

Relative Strength
83
out of 99
Market Leader
Trend Score
3/4
Minervini Criteria
EMERGING TREND
Risk (Beta)
0.65
vs S&P 500
DEFENSIVE
52W Position
65%
from 52W low
Mid Range
Trend & Momentum Analysis

Trend Template (Minervini)

EMERGING TREND3/4 Criteria Met
CriterionValueStatus
Price > 50 SMA$3.57
50 SMA > 100 SMA$3.14
100 SMA > 150 SMA$3.01
150 SMA > 200 SMA$2.73

Price vs Moving Averages

PeriodValueSpreadSignal
20 SMA$3.40+0.44%ABOVE
50 SMA$3.57-4.31%BELOW
100 SMA$3.14+8.98%ABOVE
150 SMA$3.01+13.45%ABOVE
200 SMA$2.73+25.27%ABOVE

Price Performance

1D-2.8%
1W-0.9%
1M+1.2%
3M+21.3%
6M+41.3%
YTD-15.1%
1Y+117.8%
3Y-33.3%
52-Week Trading Range65% from low
$3.42
52W Low$1.33
52W High$4.53

Technical Indicators

RSI (14)NEUTRAL
51.9
305070
VCP ScoreCOOL
4/10
Base depth: 59.8%

Risk Profile

Beta
0.65
52W Vol
79%
ATR
$0.27
Max DD (1Y)
-39%

Volume Analysis

Today
3
50D Avg
729.0K
Vol Ratio
0.00x
Liquidity
ILLIQUID

Earnings Momentum

Q4'24+69%
$-0.37
Q1'25+53%
$-0.48
Q2'25+162%
$0.45
Q3'25+114%
$0.11
Fundamentals & Growth

Growth Trends

Compounded Sales Growth

10 Years:—
5 Years:+9.50%
3 Years:-5.71%
TTM:-0.32%

Compounded Profit Growth

10 Years:—
5 Years:—
3 Years:—
TTM:+92.18%

Stock Price CAGR

10 Years:-22.29%
5 Years:-43.27%
3 Years:-33.35%
1 Year:+117.83%

Return on Equity

10Y Avg:-84.9%
5Y Avg:-90.7%
3Y Avg:-148.9%
Last Year:6.1%

Key Metrics

Market Cap$95M
Gross Margin63.8%
Net Margin-79.8%
Piotroski F-Score1/9

More FBIO Analysis

Full Financial AnalysisDCF & Intrinsic ValueTotal Return Calculator

Compare With

FBIO vs REGNREGNCNTAIMNMCLDX

Data Dictionary

RS Rating (Relative Strength)

Measures 12-month price performance vs all stocks. Rating of 83 meansFBIO outperformed 83% of all stocks. Scores >80 indicate market leaders.

Beta

Measures volatility vs S&P 500. Beta of 0.65 means 35% less volatile than market.

Piotroski F-Score

9-point financial strength score based on profitability, leverage, and efficiency. Score of 1/9. Scores 7-9 = strong, 4-6 average, 0-3 = weak.

VCP (Volatility Contraction Pattern)

Measures base formation quality. Higher scores indicate tighter consolidation near pivot points. Score of 4/10 with COOL status.

Frequently Asked Questions

Is FBIO in an uptrend right now?

FBIO has a trend score of 3/4 based on Minervini's Stage Analysis. Currently showing partial alignment - 3 of 4 trend criteria are met.

Is FBIO overbought or oversold?

FBIO's RSI (14) is 52. The stock is in neutral territory, neither overbought nor oversold.

Is FBIO outperforming the market?

FBIO has a Relative Strength (RS) Rating of 83 out of 99. Yes, FBIO is a market leader, outperforming 83% of all stocks over the past 12 months.

Where is FBIO in its 52-week range?

FBIO is trading at $3.42, which is 75% of its 52-week high ($4.53) and 65% above its 52-week low ($1.33).

How volatile is FBIO?

FBIO has a Beta of 0.65 and 52-week volatility of 79%. It's less volatile than the S&P 500 - generally more stable.